"10.1371_journal.pone.0055741","plos one","2013-02-21T00:00:00Z","Michael F Hill; Amish V Patel; Abigail Murphy; Holly M Smith; Cristi L Galindo; Laura Pentassuglia; Xuyang Peng; Carrie G Lenneman; Oghenerukevwe Odiete; David B Friedman; Marvin W Kronenberg; Siyuen Zheng; Zhongming Zhao; Yanna Song; Frank E Harrell; Maya Srinivas; Anindita Ganguly; Jennifer Iaci; Tom J Parry; Anthony O Caggiano; Douglas B Sawyer","Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America; Department of Biochemistry, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America; Biomedical Informatics and Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America; Acorda Therapeutics, Inc., Hawthorne, New York, United States of America","Conceived and designed the experiments: MFH AVP AM HMS CLG LP XP CGL OO DBF MWK SZ ZZ YS FEH MS AG JI TJP AOC DBS. Performed the experiments: MFH AVP AM HMS CLG LP XP CGL OO DBF MWK SZ ZZ DBS. Analyzed the data: MFH AVP AM HMS CLG LP XP CGL OO DBF MWK SZ ZZ YS FEH MS AG JI TJP AOC DBS. Contributed reagents/materials/analysis tools: DBF SZ ZZ YS FEH MS AG JI TJP AOC. Wrote the paper: MFH AVP AM HMS CLG LP XP CGL OO DBF MWK SZ ZZ YS FEH MS AG JI TJP AOC DBS.","Douglas Sawyer has received research support from Acorda Therapeutics, Inc. that helped to fund parts of this study. Several authors as noted on the title page are employees of Acorda Therapeutics, Inc., a company that is developing GGF2 for the treatment of cardiovascular and neurodegenerative disease. The authors note that these competing interests do not alter their adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","02","Michael F Hill","MFH",21,TRUE,21,14,21,21,TRUE,TRUE,FALSE,0,NA,FALSE
